---
schema_version: "1.0.0"
document_id: "d3f5ff9094f62b771e2350075aa9ae7ffb71a4800a12f1de1b8a70ec8c17c87f"
company_key: "yc-medcrypt"
company: "MedCrypt"
source_id: "yc-medcrypt-news-import-56918f8bbce9"
canonical_url: "https://www.medcrypt.com/blog/devsecops-medical-devices-ship-fast-prove-it-easily"
published_at: "2025-09-15T00:00:00+00:00"
first_seen_at: "2026-07-22T03:50:59.950031+00:00"
fetched_at: "2026-07-28T22:01:02.064378+00:00"
content_hash: "sha256:17c9c2314864b807e6dd1f2324818b5602e895272c2776b75612056e938ce4fd"
---

# DevSecOps for Medical Devices: Ship Fast. Prove it Easily.

The “good enough for SaaS” approach won’t work for the FDA. Here’s how Helm transforms security into submission‑ready evidence.


## **TL;DR**


- Medical device DevSecOps lives under a **dual mandate** : deliver quickly *while* documenting everything defensibly.
- Standard SCA/SAST tools can find issues, but they fall short. They **don’t explain risk in the context of your device** or generate FDA‑ready evidence.
- **Helm** bridges engineering and regulatory affairs/ quality assurance (RA/QA): It merges multiple SBOMs, prioritizes vulnerabilities by device impact, captures justifications, and exports evidence packs you need for eSTAR or audits.
- Rollout in **30 days** : connect CI/CD → triage with policy → standardize evidence → scale across your entire product portfolio.


**One workflow, two stakeholders.** Engineers keep velocity; RA/QA gets proof.


## **Why DevSecOps in MedTech “hits different”**


Shipping secure code is a basic requirement everywhere. In regulated healthcare, however, you also need a **traceable story** for every decision that impacts patient safety:


- *Why* a vulnerability wasn’t patched
- *How* it is mitigated
- *Where* it exists in the product lineage (CVE → component → device version)
- *Who* reviewed and approved the decision, and *when*


That’s the critical difference between “secure enough to ship” and **defensible enough to submit** .


## **The SBOM Reality (and why SCA isn’t enough)**


Modern medical devices have complex stacks: real‑time OSs, third‑party libraries, optional attachments, and field‑configurable variants. One device often means **multiple SBOMs** - and thousands of CVEs.


SCA tools are great at **finding** vulnerabilities, but they can’t answer questions that regulators and customers will ask:


- Is this issue **exploitable in *your* device** ?
- If not patched, **what’s the rationale** ?
- Which **compensating controls have you put in place to** reduce risk?
- Show the **version‑to‑version change history** and approvals.


**Bottom line:** You don’t need more alerts - you need **evidence** .


## **Shift‑Left, Submit Right: The Helm Workflow**


Helm connects your engineering reality to regulatory expectations in one flow.


### **1) Plug into CI/CD**


- **Auto‑ingest SBOMs** at build
- **Gate releases** on policy (exploitability, severity, component age)
- **Flag risky diffs** before they hit main


### **2) Triage What Matters**


- AI explanations **tuned to your device**
- Prioritize exploitability + impact, not just CVSS
- Fast **suppress/accept** with required rationale


### **3) Capture the Evidence**


- Standardized **justification templates** (“why we didn’t patch”)
- **Compensating controls** (e.g., process isolation, ACLs) auto‑attached
- **Reviewer sign‑off** + timestamps + linked artifacts


### **4) Maintain Traceability**


- Link **CVE → component → device version** across variants
- Keep **diffs and approvals** by release
- **Reuse justifications** across similar builds


### **5) Export FDA‑Ready Evidence**


- One‑click **evidence packs** suitable for submissions and audits
- **Versioned archives** and consistent templates
- Portfolio‑level rollups for exec and customer reporting


## **See results in 30‑Days | Practical and Measurable**


**Goal:** Stand up a repeatable DevSecOps workflow that produces submission‑ready evidence mapped to FDA expectations (2025 Premarket Cybersecurity Guidance + FD&C Act §524B).


**FDA measure supported:** **FDA‑Aligned KPIs**


- **eSTAR/Technical Screening Cybersecurity Completeness ≥ 90%** (no “missing cybersecurity content” holds).
*Supports* Premarket Guidance **Appendix 4** documentation elements & **D. Submission Documentation** ; aligns to eSTAR technical screening expectations.
- **SBOM Coverage ≥ 95%** across device + variants/attachments (machine‑readable with required fields).
*Supports* **§524B(b)(3)** SBOM + Premarket Guidance **V.A.4(b)** .
- **Median Time‑to‑Triage for exploitable HIGH CVEs ≤ 5 business days** ; **plan established ≤ 10 business days** (patch or compensating control).
*Supports* **§524B(b)(1)** plans/procedures with documented **timelines** for patches/updates; Premarket Guidance **VI.B** .
- **Justifications captured for ≥ 95% of accepted/suppressed items** , with linked controls and approver sign‑off.
*Supports* Security Risk Management documentation ( **V.A.2, V.A.6** ) and **§524B(b)(2)** reasonable assurance.
- **Traceability completeness ≥ 95%** (CVE → component → device version links).
*Supports* Premarket Guidance **Appendix 4** documentation elements; transparency across TPLC.
- **Rework due to missing evidence ↓ QoQ** (target: −50% by Q2).
*Supports* Premarket Guidance **D. Submission Documentation** and **Appendix 4** consistency—reducing deficiencies.


## **Example: When FDA Asks “Why Didn’t You Patch?”**


**Context:** CVE‑20XX‑YYYY in openssl/libcrypto version 1.1.1u.
**Device impact:** The vulnerable code path is not network‑reachable in this device; TLS terminates upstream on a segregated module.
**Decision:** **Accept** with compensating controls.
**Evidence captured in Helm:**


- Rationale: Not externally reachable; mitigated by **process isolation** + strict ACLs
- Linked artifacts: Architecture diagram, test results, SBOM snapshot
- Reviewer sign‑off: Security lead + RA/QA approver with timestamps
- Trace link: CVE → component → Device XYZ v2.3.0
- Status: Accepted w/ Compensating Controls; review in next release cycle


This is the **difference** between “we decided” and **“we can prove it.”**


‍


## **What Each Stakeholder Cares About**


Helm is engineered so **neither side has to compromise** .


## **FAQs**


**“We already have an SCA tool.”** Great - keep it. Helm **adds device context and evidence** (rationale, controls, approvals, exports) so you can submit defensibly.


**“Won’t this slow engineering down?”** Policy gates and AI‑assisted explanations **reduce** triage time and make decisions repeatable - so you lose less time before release.


**“We have dozens of variants - how do we keep up?”** Helm merges multiple SBOMs, tracks component lineage, and lets you **reuse justifications** across similar builds.


**“What about legacy devices?”** Use Helm to build **posture baselines** , document mitigations, and prioritize high‑impact fixes while keeping a paper trail for customers and regulators.
